# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today presented new data on the potential anti-inflam...
HC Wainwright & Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:ALT) with a Buy and maintains $12 price target.
JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price targ...
Cramer discusses Agnico Eagle Mines, Nutanix, Altimmune, CVR Energy and Quanta Services on CNBC's "Mad Money."